How transcription factor mutations shape diabetes risk
Diabetes affects hundreds of millions of people worldwide. The disease features elevated blood glucose levels and disrupted fat and protein metabolism. The musculoaponeurotic fibrosarcoma, or MAF, family of transcription factors regulate various processes in tissue development, including hormone production in pancreatic islet cells. Within this family, MAFA and MAFB are essential for development and maturation of insulin- and glucagon-producing cells.
Previous research showed that MAFA and MAFB expression is affected in diabetes, both Type 1 and Type 2. In addition, a mutation in MAFA that prevents phosphorylation of a key serine residue causes monogenic diabetes. Mutation of the equivalent residue in MAFB leads to a pediatric multisystem disorder. In a recent Journal of Biological Chemistry article, Jeeyeon Cha, Xin Tong and Katie Coate from Vanderbilt University and collaborators in the U.S. examined how mutations in conserved DNA-binding domains of the MAF proteins impact their regulation of the insulin gene. The authors used targeted mutagenesis and artificial intelligence structure prediction using AlphaFold 2 for their analysis.
They found one MAFA variant, with a mutation in the conserved DNA-binding region, that exhibited normal activity. The equivalent mutation in MAFB did not retain normal activity. Therefore, the researchers searched for structural differences between the MAFA and MAFB proteins outside of the DNA-binding region that might also contribute to its activity. Their AlphaFold 2 models showed that the two proteins differed in the C-terminal domains. The researchers created chimeras by exchanging the two C-terminal domains of MAFA and MAFB, which changed how each protein regulated the insulin gene. These results help clarify differences between MAFA and MAFB, which of their domains affect activity and possible ways that they contribute to different disease states.
Future studies will focus on regions of MAFA and MAFB that may interact with other coregulators of the insulin gene.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Building a better model for drug delivery across the blood–brain barrier
Industry and academic scientists collaborated to develop a rat with humanized iron-transport receptors, enabling research into iron homeostasis and drugs that cross the brain’s barrier.
Fat synthesis enzyme crucial for milk fat and newborn growth
Researchers found that a deficiency of the fatty acid synthesis enzyme stearoyl-CoA desaturase-1 reduced mammary gland function during lactation and caused low birth weight in newborns that were fed milk from enzyme-deficient glands.
Flipping lipids and slime molds
A dull first job nearly pushed JBC associate editor Todd Graham out of science. Then a slime mold project changed his path. Now, he studies membrane biology and reflects on discovery, persistence and mentoring through uncertainty.
How smelling death alters worm behavior
Researchers have found that the roundworm C. elegans can smell death, and it changes how the worms behave, reproduce and age.
A chance encounter with the lab
Payton Stevens never planned to become a pancreatic cancer researcher. A temporary job set him on a path from rural Kentucky to leading research on Wnt signaling and metastasis, where he now pairs discovery with mentorship and science advocacy.
Light-activated small molecule could transform eye infection treatment
Contact lenses raise the risk of infectious keratitis, a leading cause of blindness worldwide. A biotech company is commercializing a light-activated therapy using a ROS-generating molecule to rapidly kill microbes in the cornea to preserve vision.